Clinical Trial Search

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Participants With Treatment-Emergent Adverse Events (TEAEs) — 24; 15; 15; 15 Participants

Primary: Phase I: Number of Patients With Dose-limiting Toxicity (DLT) — 2; 2; 2 Participants

Primary: Percentage of Participants Experiencing Response — 38.9; 31.3; 76.5; 6.3 Percentage of participants

Primary: Percentage of Participants With Grades II to IV aGVHD at Day +100 of Atorvastatin Administration — 30 percentage of patients

Primary: Using a Patient Rated Subjective Scale (Visual Analogue Scale), Change From Baseline With Botulinum Toxin Therapy Plus Occupational Therapy Compared to Botulinum Toxin…

Primary: Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) — -40.2; -55.0; -56.8…

Primary: Visual Analog Scale for Pain Score — 59.3; 30.3; 55.0; 75.0 units on a scale

Primary: Maximum Tolerated Dose (MTD) — 105 mg/m^2

Primary: Global Severity Score on the Y-GTSS — 80.25; 78.75; 61; 69.75 units on a scale

Primary: Progression-free Survival Rate at 3 Years — 92.2; 93.7; 58.8 percentage of participants

Primary: Post-operative Opioid Use — 10.59; 15.62; 16.09; 32.24 mg

Primary: Area Under the Curve (AUC) Plasma Glucose — 26994.7; 32122.2 mg*min/dL

Primary: Event-free Survival (EFS) — 0; 24; 24 Participants

Primary: Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 2; 4 Participants